Cranberries improve postprandial glucose excursions in type 2 diabetes
Jace Schell1, Nancy M Betts, Megan Foster
1Department of Nutritional Sciences, College of Human Sciences, Oklahoma State University, Stillwater, OK, USA. arpita.basu@okstate.edu.
Food & Function
|July 28, 2017
Summary
Dried cranberries improved postprandial glucose control and reduced inflammation markers in individuals with type 2 diabetes after a high-fat meal. This suggests whole cranberries may benefit cardiometabolic health.
Area of Science:
- Nutrition Science
- Cardiovascular Health
- Metabolic Disorders
Background:
- Postprandial hyperglycemia is an independent cardiovascular risk factor.
- Berries, including cranberries, show potential in improving postprandial dysmetabolism.
- Few studies have investigated cranberry's effects on postprandial metabolism in type 2 diabetes.
Purpose of the Study:
- To investigate the postprandial effects of dried cranberries following a high-fat meal in obese participants with type 2 diabetes.
- To assess the impact of cranberries on glucose, insulin, lipid profiles, blood pressure, and biomarkers of inflammation and oxidation.
Main Methods:
- A randomized crossover trial involving 25 obese participants with type 2 diabetes.
- Participants consumed a high-fat breakfast with or without 40g of dried cranberries.
- Blood and vascular measurements were taken at fasting and 1, 2, and 4 hours post-meal.
Main Results:
- Cranberries significantly reduced postprandial glucose levels at 2 and 4 hours compared to the control.
- Interleukin-18 and malondialdehyde levels were lower, and total nitrite was higher post-cranberry consumption.
- No significant differences were observed in insulin, insulin resistance, lipid profiles, or blood pressure.
Conclusions:
- Dietary cranberries improved postprandial glucose management after a high-fat meal in individuals with type 2 diabetes.
- Cranberries positively influenced selected biomarkers of inflammation and oxidation.
- Adding whole cranberries to high-fat meals may be a beneficial dietary strategy for managing postprandial glucose, warranting further research.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
477
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
477
01:22Diabetes Mellitus: Type 2 and Gestational
4.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.2K
01:24Glucagon-like Receptor Agonists
775
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
775
01:16Hormones Regulating Blood Glucose
6.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
6.1K
01:36Carbohydrate Metabolism
13.6K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
13.6K
01:23Dipeptidyl Peptidase 4 Inhibitors
508
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
508